The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly
because of the expanding indications for standard-of-care treatment and the development of …

To the extent that pharmacokinetics influence the effectiveness of nonliving therapeutics, so
too do cellular kinetics influence the efficacy of Chimeric Antigen Receptor (CAR)-T cell …

Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer
immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the …

CD19-and B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T
cells have enabled unprecedented responses in a subset of refractory patients with B-cell …

Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy for
relapsed or refractory large B-cell lymphoma (LBCL). This study evaluated whether immune …

The phase 3 ZUMA-7 trial in second-line large B cell lymphoma demonstrated superiority of
anti-CD19 CAR T cell therapy (axicabtagene ciloleucel (axi-cel)) over standard of care …

PURPOSE Although the majority of patients with relapsed or refractory large B-cell
lymphoma respond to axicabtagene ciloleucel (axi-cel), only a minority of patients have …

The relative efficacy of autologous hematopoietic cell transplant (auto-HCT) vs chimeric
antigen receptor T-cell (CAR-T) therapy in patients with diffuse large B-cell lymphoma …

Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric
antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell …

CD19-directed chimeric antigen receptor (CAR-19) T cells are groundbreaking
immunotherapies approved for use against large B-cell lymphomas. Although host …